Bcl-2 Inhibits the Mitochondrial Release of an Apoptogenic Protease

By Santos A. Susin,* Naoufal Zamzami,* Maria Castedo,∗ Tamara Hirsch,* Philippe Marchetti,* Antonio Macho,* Eric Daugas,* Maurice Geuskens,‡ and Guido Kroemer*

From the *Centre National de la Recherche Scientifique-UPR 420, F-94801 Villejuif, France; and the ‡Department of Molecular Biology, Université Libre de Bruxelles, 1640 Rhode-Saint-Genèse, Belgium

Summary
Bcl-2 belongs to a family of apoptosis-regulatory proteins which incorporate into the outer mitochondrial as well as nuclear membranes. The mechanism by which the proto-oncogene product Bcl-2 inhibits apoptosis is thus far elusive. We and others have shown previously that the first biochemical alteration detectable in cells undergoing apoptosis, well before nuclear changes become manifest, is a collapse of the mitochondrial inner membrane potential (ΔΨm), suggesting the involvement of mitochondrial products in the apoptotic cascade. Here we show that mitochondria contain a pre-formed ~50-kD protein which is released upon ΔΨm disruption and which, in a cell-free in vitro system, causes isolated nuclei to undergo apoptotic changes such as chromatin condensation and internucleosomal DNA fragmentation. This apoptosis-inducing factor (AIF) is blocked by N-benzyloxycarbonyl-Val-Ala-Asp.fluoromethylketone (Z-VAD.fmk), an antagonist of interleukin-1β-converting enzyme (ICE)-like proteases that is also an efficient inhibitor of apoptosis in cells. We have tested the effect of Bcl-2 on the formation, release, and action of AIF. When preventing mitochondrial permeability transition (which accounts for the pre-apoptotic ΔΨm disruption in cells), Bcl-2 hyperexpressed in the outer mitochondrial membrane also impedes the release of AIF from isolated mitochondria in vitro. In contrast, Bcl-2 does not affect the formation of AIF, which is contained in comparable quantities in control mitochondria and in mitochondria from Bcl-2-hyperexpressing cells. Furthermore, the presence of Bcl-2 in the nuclear membrane does not interfere with the action of AIF on the nucleus, nor does Bcl-2 hyperexpression protect cells against AIF. It thus appears that Bcl-2 prevents apoptosis by favoring the retention of an apoptogenic protease in mitochondria.

Before cells manifest nuclear signs of apoptosis, they disrupt the mitochondrial transmembrane potential (ΔΨm). This pre-apoptotic ΔΨm collapse occurs in numerous cell types (neurons, fibroblasts, myelomonocytic cells, lymphocytes, hepatocytes), irrespective of the apoptosis inducer or the presence of mitochondrial DNA (1-5 and references cited therein). As to the mechanism of the pre-apoptotic ΔΨm disruption, it appears that it is mediated by so-called “permeability transition (PT) pores”, i.e., regulated megachannels that allow for the dissipation of inner transmembrane ion gradients. Thus, a series of drugs known for their PT-inhibitory potential (6, 7) such as cyclosporin A (which acts as a transient inhibitor of PT, via mitochondrial cyclophilin) or bongkrekic acid (which acts as a stable inhibitor of PT, via specific binding to the inner membrane adenine nucleotide translocator) inhibit the pre-apoptotic ΔΨm collapse (2, 4). Bonkrekic acid is also an efficient inhibitor of other manifestations of apoptosis at the levels of the nucleus (chromatin condensation and DNA fragmentation), of the cytoplasm (depletion of non-oxidized glutathione and hyperproduction of reactive oxygen...
species), and of the plasma membrane (exposure of phosphatidylserine residues in the outer membrane leaflet, increase in permeability) (4, 8). Altogether these findings suggest that mitochondrial PT may be an important common event of the effector phase of the apoptotic process. This idea is underlined by the observation that mitochondria undergoing PT acquire the capacity to induce nuclear apoptosis in an in vitro system (4). A further argument in favor of the implication of PT in apoptosis regulation is the finding that the apoptosis-inhibitory proto-oncogene product Bcl-2 functions as an endogenous PT inhibitor. This PT-inhibiting activity is due to the fact that mitochondrial PT may be an important common event of the effector phase of apoptosis. In this cell line, Bcl-2 overexpression confers resistance to most but not all apoptosis-inducing stimuli (18). These cell lines, as well as isolated mitochondria (4), suggest that PT may indeed constitute the (or one of the) Bcl-2-regulated apoptotic checkpoint(s) of the apoptotic cascade. It has remained obscure, however, how the putative Bcl-2/PT checkpoint could be related to another apoptosis checkpoint controlled by a cascade of proteases belonging to the expanding ICE/CPP32/Ced-3 family (9–11), especially in view of the fact that Bcl-2 can regulate the activation of at least some of these proteases (12).

Based on the findings of other investigators (13–17), we have recently developed a cell-free system of apoptosis. Using such a system, we observed that isolated mitochondria induced to undergo PT in vitro release a heat-labile >10-kD factor capable of inducing isolated nuclei to rapidly (≤15 min) manifest apoptotic changes such as chromatin condensation and oligonucleosomal DNA fragmentation (4). This finding suggested a direct molecular link between pre-apoptotic Δψm disruption and nuclear apoptosis. In the present paper, we report the biochemical characterization of the apoptogenic factor released by mitochondria. Intriguingly, this factor possesses a protease activity which is neutralized by a degenerate tripeptide inhibitor of ICE-like proteases, suggesting a direct relationship between PT and protease activation during the effector phase of apoptosis. In addition, we characterized the effect of Bcl-2 on the production, release, and action of this mitochondrial apoptotic-inducing factor (AIF). Our data indicate that Bcl-2 solely interferes with the PT-dependent release of AIF, yet does not neutralize its lethal action. These data may provide major clues for the understanding of apoptosis regulation.

**Materials and Methods**

**Organs and Cell Lines.** Livers were obtained from female Balb/c mice (6–8 wk of age) subjected to perfusion of the portal vein with isotonic PBS (pH 7.2; 5 ml at room temperature). 2B4.11 T cell hybridoma cell lines stably transfected with an SFFV.neo vector containing the human bcl-2 gene or the neomycin (Neo) resistance gene only were kindly provided by Jonathan Ashwell (National Institutes of Health, Bethesda, MD). In this cell line, Bcl-2 overexpression confers resistance to most but not all apoptosis-inducing stimuli (18). These cell lines, as well human fibroblast-like HeLa cells, were cultured in RPMI1640 medium supplemented with l-glutamine, antibiotics, and 10% decomplemented FCS.

**Induction of Apoptosis in Cells.** T cell hybridoma cells were cultured during 8 h in the presence of the indicated concentration of ter-butyldihydroperoxide (t-BHP), carbonylcyanide m-chlorophenylhydrazone (mCCCP), C2-ceramide (Sigma, Chem Co., St. Louis, MO), N-benzoyloxycarbonyl-Val-Ala-Asp.fluoromethylketone (Z-VAD.fmk; Enzyme Systems, Dublin, CA), and/or the membrane-permeant specific inhibitor of interleukin-1β-converting enzyme (ICE) Ac-YVAD.cmk (Bachem, Basel, Switzerland). The frequency of subdiploid cells was determined by propidium iodine staining of ethanol-fixed cells. In some experiments, Bcl-2-or vector-transfected cells (1 × 10⁶) were permeabilized with saponin (5 mg/ml) in the presence of CFS buffer (see below) or purified AIF (1 μg/300 μl), then washed twice (1,000 g, 10 min), and cultured for 60 min in CFS buffer. Then, DNA fragmentation was assessed using terminal deoxynucleotidyltransferase to incorporate Fluorescein-12-dUTP into permeabilized cells, following the manufacturer's protocol (TUNEL method; Boehringer Mannheim, Mannheim, Germany).

**Purification of Organelles.** Mitochondria were purified on a Percoll® (Pharmacia, Uppsala, Sweden) gradient (19) and were stored on ice in B buffer (400 mM mannitol; 10 mM KH₂PO₄, 5 mg/ml BSA, 50 mM TRIS-HCl, pH 7.2) for up to 4 h. Mitochondria were washed and resuspended in cell-free system (CFS) buffer (220 mM mannitol; 68 mM sucrose, 2 mM NaCl, 2.5 mM PO₄.H₂O, 5 mM EGTA, 2 mM MgCl₂, 5 mM pyruvate, 0.1 mM phenylmethylsulfonfluoride [PMSF], 1 mM dithiotreitol, 10 mM Hepes-NaOH, pH 7.4) before manipulation (4). Submitochondrial fractions were obtained as described (20). Osmotic shock of mitochondria leading to the disruption of the outer but not of the inner membrane or digitonin lysis (1.2%) of the outer mitochondrial membrane for the obtention of intermembrane proteins was performed according to standard methods (20). The four mitochondrial compartments (inner + outer membrane, intermembrane, matrix) were identified by the specific activities of the marker enzymes monoamine oxidase (MAO) for the outer membrane, succinate dehydrogenase (SDH) for the inner membrane, and malate dehydrogenase (MDH) for the matrix (21). Enzyme activities were determined as described (21) and expressed as specific activities (nmol of transformed substrate × mg⁻¹ protein × min⁻¹).

**Determination of Apoptotic Effects on Isolated Nuclei.** For the standard assessment of chromatin condensation, nuclei from HeLa cells were purified on a sucrose gradient and conserved in 50% glycerol (Sigma) in HNB buffer, at 20°C for a maximum of 15 d, as described (13, 23). The expression of Bcl-2 on the surface of isolated mitochondria or nuclei was determined using an FITC-labeled hBcl-2-specific antibody (1 μg/ml, 30 min at 4°C, clone 124; DAKO, Glostrup, Denmark).
ation and/or a translucent aspect were interpreted as being apopto-
tic (4). Alternatively, nuclei were stained with propidium iodide
(P1; 10 μg/ml; Sigma) and the lipophilic dye 5-methyl-bodipy-
3-dodecanoic acid (100 nM; Molecular Probes), followed by
fluorescence microscopy in a EPICS Profile II Analyzer (Coulter,
Hialeah, FL). Only membrane-surrounded (5-methyl-bodipy-
3-dodecanoic acid-labeled) particles were gated on. A good cor-
relation between the frequency of nuclei exhibiting chromatin
condensation with DAPI and hypoploidy with PI was obtained
(S.A. Susin and G. Kroemer, manuscript in preparation). In one
series of experiments, nuclei from Neo- or Bcl-2-transfected
T cell hybridoma cells were subjected to transmission electron
microscopy, as described (8). Furthermore, in one experiment,
nuclei were pretreated with Z-VAD.fmk (1 mM, 60 min, 37°C
in CFS buffer), washed 3× (1000 g; 10 min), and exposed to mi-
chondrial factors.

Purification of the Mitochondrial Apoptosis-inducing Factor (AIF).

Purified hepatocyte mitochondria were treated with atracylsiside
(5 mM; Atr; Sigma) to induce PT and liberation of AIF (4). Su-
pernatants (150,000 g; 1 h; 4°C) from these mitochondria were
concentrated on Centricon 10 membranes (≥10 kD; Amicon
Inc., Beverly, MA), which retains the entire AIF activity (4), and
then subjected to a Pharmacia MonoQ (HR5/5) FPLC column
pre-equilibrated with protein-free CFS buffer. Elution was per-
formed on a linear gradient from 0 to 250 mM NaC1 at 0.5 ml/
min over 30 min, followed by elution at 1 M from min 33. After
dialysis (10 kD membrane) in CFS buffer, all fractions were sub-
jected to the asessment of pro-apoptotic activity. The active frac-
tion (eluting at 110 mM NaC1) was dialedyzed against protein-free
CFS buffer (4°C, 4 h, 5,000× excess of CFS buffer) and sub-
jected to re-injection into the Pharmacia MonoQ FPLC column
(5 μg; elution as described above) or a reverse phase C-18 col-
umn coupled to a Hewlett Packard 1090 HPLC apparatus (eluted
on a linear gradient from 0.1% trifluoracetic acid in water to 0.1%
trifluoracetic acid in acetonitrile at 1 ml/min over 30 min). The
SDS-PAGE (12%; performed in reducing conditions: 1 mM
dithiothreitol) of AIF purified by anion exchange chromatography
(concentrated on a Centricon 10 membrane; 2 μg) was subjected
to Silver staining (Biorad, Hercules, CA). Alternatively, AIF-
containing supernatants or AIF purified on the MonoQ column
were fractionated on a Pharmacia Superdex75 column equili-
brated with CFS buffer. All fractionation steps had to be carried
out at 4°C to avoid loss of biological AIF activity. To determine
the inhibitory profile of AIF, different protease inhibitors were added
to purified AIF or AIF-containing preparations: Z-VAD.fmk,
N-benzoyloxy carbonyl-Phe-Ala-fluoromethylketone (Z-FA.fmk;
Enzyme Systems), N-tosyl-l-Lys-chloromethylketone (TLCK;
Sigma), N-tosyl-l-Phe-chloromethylketone (TPCK), E64, leupeptin,
p-chloromercuribenzenesulfonic acid, N-phenylmaleimide
(Sigma), calpain inhibitors I and II (Boehringer), or modified tet-
sapides and N-benzoyloxy carbonyl-Asp-CH_2-OOC(2-6)-dichlo-
robenzene (Z-D.CH2-dcb; Bachem).

Quantitation of Mitochondrial Pore Permeability Transition (PT).

For the induction of PT, mitochondria from different cell lines were
incubated with the indicated doses of Atr, t-BHP or mCCICP (4).
The ΔΨ_m was measured using the ΔΨ_m-sensitive cationic lipoph-
lic dye chloromethyl-X-rosamine (CMXRos; 10 nM; 15 min
at 37°C; Molecular Probes) (5), after having added the indicated
PT inducer (15 min, 37°C). Mitochondria were analyzed in an
Elite cytofluorometer (Coulter). All ΔΨ_m determinations were
performed at least three times in each experiment.

Determination of Protease and DNAase Activity. AIF-mediated cleav-
age of nuclear substrates is indicated by the comparative analysis of
Coomassie-stained SDS-PAGE of HeLa nuclei (5 × 10⁶/lane) cul-
tured in the presence or absence of 100 ng/ml purified AIF (90 min,
37°C). The degree of poly(ADP-ribose) polymerase (PARP) and
lamin cleavage was determined by immunobots, using the mono-
clonal antibodies C2-10 (purchased from Guy Poirier, Montreal
University, Canada) and E6 (kind gift from Dr. E. Nigg, Lau-
sanne University, Lausanne, Switzerland), respectively (14, 24,
25). Positive controls were human T lymphoma cells exposed to
anti-Fas antibody (300 ng/ml; 4 h; Immunotech, Marseille,
France). Endonuclease activity was determined on supercoiled
pUC DNA (500 ng in CFS buffer; 120 min; 37°C), followed by
ethidium bromide agarose gel (1%) electrophoresis.

Results

Localization and Purification of AIF. Supernatants from mitochon-
dria that have undergone PT but not those from control mitochondria induce signs of apoptosis such as nuclear
chromatin condensation in a cell free system (4). Thus, mitochondria treated with the PT inducers atracylsiside
(Atr, a specific ligand of the adenine nucleotide transloca-
tor), mCCICP (a protonophore) and t-BHP (a pro-
oxidant) release an apoptogenic activity into the superna-
tant that we have baptized “apoptosis-inducing factor”
(AIF)(Fig. 1). In addition to these PT-inducing treatments,
destruction of mitochondrial membranes via sonication, os-
motic shock, or digitonin treatment (which specifically
lyses the outer but not the inner membrane, yielding the
intermembrane fraction of proteins) (20) also releases AIF,
indicating that AIF is pre-formed. Whereas, the fraction of
soluble intermembrane products does contain AIF activity,
neither purified mitochondrial membranes nor the soluble
products of the mitochondrial matrix are apoptogenic (Fig. 1,
Table 1). Thus, AIF is not found in submitochondrial frac-
tions that contain high specific activities of marker enzymes
for the outer membrane (MAO), inner membrane (SDH),
and matrix (MDH) (Table 1). Protease K treatment of in-
termembrane proteins destroys AIF activity, indicating that
AIF is a protein (Fig. 1). Ion exchange chromatography
yields only one AIF activity which elutes at 110 mM NaC1
(Fig. 2 A). The AIF-containing fraction purified on an an-
ion exchange column contains only one major protein as
determined by four different methods: reinjection into the
same anion exchange FPLC column (Fig. 2 B), analysis on a
reverse phase HPLC column (which separates proteins
based on their hydrophobicity; Fig. 2 C), separation in a
molecular sieve FPLC column (Fig. 2 D) and SDS-PAGE
revealed by the sensitive silver staining technique (Fig. 2 E).
Thus, anion exchange chromatography (Fig. 2 A), molecular
sieve chromatography (Fig. 2 D), and SDS-PAGE (Fig. 2 E)
identify hepatocyte AIF as a single ~50-kD protein with an
estimated isoelectric point of 3.5. AIF purified from an
anion exchange column (Fig. 2 A) is homogenous with regard
to charge (Fig. 2 B), hydrophobicity (Fig. 2 C), and
apparent molecular weight in both denaturing and non-
denaturing conditions (Fig. 2, D and E). AIF is low-abun-
dant (<0.1% of mitochondrial proteins) and labile at room
temperature, requiring purification at 4°C. AIF activity is
Submitochondrial localization of mitochondrial apoptosis-inducing factor (AIF). Isolated HeLa nuclei were cultured in the presence of various preparations of mouse hepatocyte mitochondria: ultracentrifuged supernatants of mitochondria (10 mg protein/ml) treated with Atr (5 mM), mC1CCP (100 μM), t-BHP (50 μM), osmotic shock, or ultrasonication; soluble products (200 μg protein/ml of the mitochondrial matrix, purified inner and outer mitochondrial membranes, or soluble factors of the intermembrane space. After 90 min of culture at 37°C, the frequency of nuclei exhibiting chromatin condensation was assessed by labeling with DAPI. Proteinase K digestion of intermembrane proteins was followed by addition of 1 mM PMSF for its inactivation, as described in Materials and Methods. Representative DAPI-stained HeLa nuclei (>70% of the phenotype) cultured in the presence of untreated or proteinase K-inactivated intermembrane preparation are shown.

detected in mitochondria from several cell types (liver, heart, brain, myelomonocytic cells, lymphoid cells) and species (mouse, human), suggesting that it is an ubiquitous protein. Moreover, the physicochemical characteristics of this protein appear approximately the same for hepatocyte and lymphocyte AIF (not shown). Purified AIF suffices to induce the whole pattern of apoptotic nuclear alterations in vitro: eccentric DNA condensation resembling that observed in apoptotic cells, oligonucleosomal DNA fragmentation, and hypoploidy (Figs. 3 and 6 C; see below). In synthesis, it appears that AIF is one pre-formed, soluble mitochondrial intermembrane protein.

AIF Possesses a Proteolytic Activity That Is Inhibited by Z-VAD.fmk. To gain information on the mode of action of AIF, we determined the inhibitory profile of this factor. The chromatin condensation-inducing activity of AIF is inhibited by the thiol reagents p-chloromercuriphenylsulfonic acid (ID₅₀ ~250 μM) and N-phenylmaleimide (ID₅₀ ~50 μM) but not by specific inhibitors of different calcium, serine, or cysteine proteases including specific inhibitors of ICE (Ac-YVAD.cmk, Ac-YVAD.CHO: no inhibition at doses as high as 1 mM) and CPP32/Yama (Ac-DEVD.CHO) (reference 4 and Fig. 3 A). The only selective protease inhibitor which blocks AIF activity is Z-VAD.fmk (Fig. 3 A; ID₅₀ ~30 μM), an inhibitor of ICE-like proteases and caspases.

Figure 1. Submitochondrial localization of mitochondrial apoptosis-inducing factor (AIF). Isolated HeLa nuclei were cultured in the presence of various preparations of mouse hepatocyte mitochondria: ultracentrifuged supernatants of mitochondria (10 mg protein/ml) treated with Atr (5 mM), mC1CCP (100 μM), t-BHP (50 μM), osmotic shock, or ultrasonication; soluble products (200 μg protein/ml of the mitochondrial matrix, purified inner and outer mitochondrial membranes, or soluble factors of the intermembrane space. After 90 min of culture at 37°C, the frequency of nuclei exhibiting chromatin condensation was assessed by labeling with DAPI. Proteinase K digestion of intermembrane proteins was followed by addition of 1 mM PMSF for its inactivation, as described in Materials and Methods. Representative DAPI-stained HeLa nuclei (>70% of the phenotype) cultured in the presence of untreated or proteinase K-inactivated intermembrane preparation are shown.

Figure 2. Biochemical characterization of AIF. (A) Anion exchange purification of AIF. Concentrated supernatants from Atr-treated hepatocyte mitochondria were subjected to a MonoQ FPLC column pre-equilibrated with CFS buffer. Elution was performed on a linear gradient from 0 to 250 mM NaCl at 0.5 ml/min over 30 min while monitoring the OD₂₈₀ (full line). After dialysis (10 kD membrane) in an excess of CFS buffer, all fractions were subjected to the assessment of pro-apoptotic activity (circles). Only one fraction eluting at 110 mM NaCl was biologically active. (B) Re injection of the AIF-containing fraction eluting at 110 mM into an anion exchange column. AIF (5 μg protein) purified as in A and dialyzed in excess CFS buffer was injected into a MonoQ column in the same conditions of elution as in A, and the OD₂₈₀ was monitored. The background OD₂₈₀ obtained with CFS buffer only was subtracted. (C) Analysis of AIF (5 μg, purified on an anion exchange column as in A) in a reverse phase HPLC column, followed by monitoring of the OD₂₈₀ (background values subtracted). (D) Molecular sieve FPLC purification of AIF. AIF-containing supernatants (OD₂₈₀: full line) were fractionated on a Superdex75 column equilibrated with CFS buffer, followed by the biological assay (circles). Proteins with a known molecular weight were employed to calibrate the FPLC column (arrows). Equivalence calculations indicate that >80% of AIF activity are recovered from the columns. In addition, AIF (5 μg) purified on the anion exchange column as in A was analyzed on the Superdex 75 column while monitoring the OD₂₈₀ (dotted line). (E) SDS-PAGE of AIF (2 μg, purified as in A) in reducing conditions. Proteins were detected using a commercial Silver staining kit, as described in Materials and Methods.

1334 Mechanism of Bcl-2-mediated Apoptosis Inhibition
Table 1. Distribution of AIF in Mitochondrial Compartments

| Marker enzymes | MAO mmol/mg/min ± SD | SDH mmol/mg/min ± SD | MDH mmol/mg/min ± SD | AIF Activity % apoptosis |
|----------------|-----------------------|----------------------|----------------------|-------------------------|
| Mitochondria (freeze-thawed) | 52 ± 9 | 517 ± 149 | 2812 ± 265 | 67 ± 12 |
| Outer membrane | 503 ± 46 | 555 ± 186 | 1028 ± 364 | 14 ± 6 |
| Intermembrane space | 2 ± 1 | 10 ± 6 | 831 ± 220 | 85 ± 7 |
| Inner membrane | 2 ± 2 | 2411 ± 268 | 1416 ± 184 | <5 |
| Matrix | 1 ± 1 | <5 | 4054 ± 880 | 8 ± 3 |

Submitochondrial fractions were purified as described in Materials and Methods. Marker enzymes were measured using colorimetric approaches on synthetic substrates. AIF activity was determined for each fraction (200 μg protein/ml) as in Fig. 1. Results are mean values ± SD of four independent experiments.

(26-28). By virtue of its tripeptidic structure, Z-VAD.fmk is thought to be a less specific protease inhibitor than conventional tetrapeptidic inhibitors of ICE or CPP32/Yama (26-28). Z-VAD.fmk does not neutralize AIF by virtue of its N-benzoylcarbonyl (Z) or fluoromethylketone (fmk) groups, because the control molecule Z-FA.fmk (which only differs from Z-VAD.fmk in its amino acid sequence: FA instead of VAD) does not inhibit AIF activity at doses as high as 1 mM (Fig. 3 A and data not shown). Altogether these data suggest that AIF possesses a cysteine-dependent

![Figure 3. Inhibitory profile of AIF. (A) Screening of various protease inhibitors. Purified AIF (50 μg/ml) was tested for apoptosis-inducing activity on HeLa nuclei as in Fig. 1, in the presence of a number of different protease inhibitors. The range of negative data are shown for different inhibitors used at concentrations of either 50 μM (TLCK, TPCK, chelatin inhibitors I and II, leupeptin) or 250 μM (Ac-YVAD.cmk, Ac-YVAD.CHO). Ac-DEVD.CHO, Z-CH2-dcb, Z-FA.fmk). (B) Inhibition of the AIF activity contained in supernatants from Atr-treated mitochondria. Nuclei were treated at the same time with such supernatants and/or 100 μM Z-VAD.fmk. Alternatively, the supernatant was pretreated with Z-VAD.fmk (100 μM; 30 min, 37°C), followed by dialysis (4 h, 5,000× excess of CFS buffer) to remove Z-VAD.fmk and testing for apoptotic activity on isolated HeLa nuclei. Furthermore, nuclei were pretreated with Z-VAD.fmk (1 mM, 60 min, 37°C in CFS buffer), washed 3×, and exposed to the untreated AIF-containing supernatant. (C) Z-VAD.fmk-mediated inhibition of AIF-induced chromatinolysis. Nuclei were treated with CFS buffer only (control), purified AIF (100 ng/ml), or AIF pretreated with Z-VAD.fmk and dialyzed. Alternatively, nuclei were first treated with Z-VAD.fmk, then washed and cultured with AIF. Nuclei were stained with PI, as detailed in Materials and Methods, followed by cytofluorometric analysis. Percentages refer to the subdiploid population. (D) Z-VAD.fmk-mediated inhibition of AIF-induced DNA fragmentation. Isolated nuclei (1 × 10⁷) were cultured during 90 min in the presence of purified AIF (100 ng/ml, lanes 3 and 4) and/or Z-VAD.fmk (100 μM, lanes 2 and 4) and analyzed by ethidium bromide agarose gel electrophoresis. Positive controls (co) are human lymphoma cells exposed to anti-Fas antibody. The same three preparations were tested for endonuclease activity on pUC DNA, followed by ethidium bromide agarose gel electrophoresis.

1335 Susin et al.
catalytic activity not identical with but related to ICE and CPP32.

Z-VAD.fmk prevents the chromatin condensation induced by purified AIF as well as by supernatants from Atr-treated mitochondria (Fig. 3, B and C), in accord with the observation that AIF seems the only pro-apoptotic mitochondrial factor (Fig. 2, A and C; see above). Z-VAD.fmk is an irreversible rather than competitive protease inhibitor (26-28). Accordingly, pre-incubation of AIF with Z-VAD.fmk causes a durable AIF inactivation that persists after removal of Z-VAD.fmk (Fig. 3, B and C).

In contrast, pre-incubation of nuclei with Z-VAD.fmk has no significant protective effect against AIF (Fig. 3, B and C), thus confirming that Z-VAD.fmk acts on AIF rather than on the nuclear target(s) of AIF. Z-VAD.fmk prevents all manifestations of apoptosis induced by AIF: chromatin condensation (Fig. 3, A and B), DNA loss from nuclei (Fig. 3 C) and oligonucleosomal DNA fragmentation (Fig. 3 D).

Mitochondria contain an endonuclease which has also been found in nuclei from thymocytes (29). Accordingly, a DNAse activity is found in the supernatant of digitonin-treated mitochondria (Fig. 3 E). However, purified AIF has no intrinsic DNAse activity (Fig. 3 E), indicating that it probably induces DNA fragmentation via activating pre-existing nuclear DNases. Although AIF has a proteolytic activity on unidentified nuclear substrates of approximately 28, 42, and 90 kD (not shown), it fails to cleave PARP or lamin in isolated nuclei (Fig. 3 E). Thus, the nuclear substrate(s) of AIF must be different from those cleaved by prominent members of the ICE/CPP32 family of proteases (11, 25, 30).

If AIF was a rate-limiting factor of cell death, its inhibition should retard or inhibit nuclear apoptosis in cells. According to the literature, the AIF inhibitor Z-VAD.fmk prevents apoptosis of mammalian and insect cells responding to a variety of different lethal stimuli (26-28). In addition, as shown in Fig. 4, Z-VAD.fmk (but not its structural analogue Ac-YVAD.cmk, a specific inhibitor of ICE) inhibits apoptosis induced by ceramide, the pro-oxidant t-BHP, or the protonophore mCICCP, which acts directly on the inner mitochondrial membrane (Fig. 5). This effect is obtained at similar doses as those required to inactivate purified AIF (~60 μM) in vitro (Fig. 3 A), underlining the probable role of AIF in apoptosis.

In synthesis, it appears that mitochondria undergoing PT...
release a Z-VAD.fmk-inhibitable protease which is sufficient and probably necessary to cause nuclear apoptosis.

**Bcl-2 Prevents the Permeability Transition-dependent Release of AIF from Mitochondria.** Bcl-2 belongs to a family of apoptosis-regulatory proteins which incorporate into the outer mitochondrial membrane (31-34). Since the antiapoptotic mode of action of Bcl-2 is elusive, we addressed the question as to whether Bcl-2 inhibits apoptosis via interfering with the formation or the release of AIF. Transfection-enforced hyperexpression of Bcl-2 prevents the induction of apoptosis by t-BHP and the mitochondrion-targeted agent mC1CCP (reference 4 and Fig. 4). In addition, isolated mitochondria from bcl-2 transfected cells (which hyperexpress Bcl-2, see insert of Fig. 5 B) fail to disrupt their \( \Delta \Psi_m \) in response to Atr, the pro-oxidant t-BHP, and a low dose (10 \( \mu \)M) of the protonophore mC1CCP (Fig. 5 A), thus confirming our previous observations according to which Bcl-2 prevents the PT-dependent colloidosmotic swelling of mitochondria in vitro (4). Simultaneously, Bcl-2 overexpressing mitochondria fail to release AIF activity in response to these PT inducers (Fig. 5, B and C), underscoring the absolute correlation between PT and AIF release that we have previously reported (4). Thus, AIF is present in the supernatants of control mitochondria treated with Atr, t-BHP, or mC1CCP, yet is absent or greatly reduced in the supernatant of Bcl-2 hyperexpressing mitochondria treated with these reagents. In contrast, lysis of control and Bcl-2-overexpressing mitochondria with detergents or osmotic shock releases equal amounts of AIF activity (Fig. 5, B and C).

Thus, Bcl-2 inhibits the mitochondrial AIF release in response to determined stimuli but not the formation of AIF.

**Failure of Bcl-2 to Interfere with AIF Action on Nuclei and Cells.** The Bcl-2 p26 protein possesses a transmembrane domain allowing for its incorporation into different intracellular membranes, including the outer mitochondrial membrane, the endoplasmic reticulum, and the nuclear envelope (33, 34). We therefore addressed the possibility that Bcl-2 might antagonize the action of AIF. In a first series of experiments, nuclei were purified from control (Neo) and Bcl-2 transfected cells and cultured with purified AIF. Bcl-2 expressing nuclei (Fig. 6 A, inset) undergo apoptotic changes in response to AIF, exactly as this is the case for control nuclei (Fig. 6, A and B). Electron microscopic analysis confirmed that Bcl-2 hyperexpression does not affect the action of AIF. Both control and Bcl-2-overexpressing nuclei manifest the same pattern of chromatin

![Figure 6. Effect of Bcl-2 on AIF action in vitro. (A) Comparison of AIF effects on isolated nuclei from bcl-2-transfected and control cells cultured with different concentrations of purified AIF as in Fig. 1. The insert shows cytofluorometric profiles of nuclei stained with an anti-hBcl-2-FITC conjugate as in Fig. 5 B. (B) Comparison of DNA degradation induced in nuclei from control (1, 3) or bcl-2-transfected cells (2, 4) cultured in the absence (1, 2) or presence (3, 4) of purified AIF (250 ng/ml). (C) Comparison of the ultrastructure of nuclei from Neo- or bcl-2-transfected cells cultured in the presence or absence of AIF (250 ng/ml; 90 min). Typical cells representing the dominant phenotype (>80%) of cultures are shown.](image)

![Figure 7. Effect of Bcl-2 on AIF action in cells. Failure of Bcl-2 to induce AIF resistance in cells. Bcl-2-or vector-transfected cells were permeabilized with saponin in the presence or absence of purified AIF (1 \( \mu \)g/300 \( \mu \)l), washed, and cultured for 60 min in CFS buffer. DNA fragmentation was assessed by the TUNEL method. Numbers indicate the percentage of cells with strong DNA fragmentation.](image)
condensation (Fig. 6 C). Thus, nuclear expression of Bcl-2 does not affect the action of AIF.

Since Bcl-2 exists also in localizations outside of the nuclear and mitochondrial membrane (33), we decided to evaluate the effect of Bcl-2 overexpression on cells exposed to AIF. As shown above, AIF is a hydrophilic protein and thus does not permeate the plasma membrane. Accordingly, AIF only induces apoptotic changes in permeabilized cells (Fig. 7). Introduction of AIF into saponin-treated cells causes the same extent of DNA fragmentation in control and in Bcl-2-hyperexpressing cells (Fig. 7). Thus, Bcl-2 only acts upstream, at the level of AIF release, and has no detectable effect on AIF action, both in cells and in isolated nuclei.

Discussion

In this paper, we provide several new elements allowing for the construction of a scenario recreating the apoptotic effector phase and its regulation by the proto-oncogene bcl-2.

AIF, a Mitochondrial Apoptogenic Protease. Mitochondria undergoing PT release a protein factor, AIF, which appears to be a pre-formed, ubiquitous factor associated with the intermembrane space (Fig. 1). AIF suffices to induce typical manifestations of nuclear apoptosis in a cell-free, cytosol-free system: chromatin condensation, chromatinolysis, hypoploidy, and oligonucleosomal ladder-type DNA fragmentation (Figs. 1, 3, and 6 C). AIF lacks an intrinsic DNAse activity, yet seems capable of activating pre-formed DNAases. Intriguingly enough, all in vitro activities of AIF are blocked by Z-VAD.fmk (Fig. 3), which is also an efficient inhibitor of apoptosis in mammalian and insect cells (26–28 and Fig. 4). Although this is not a formal proof, this finding underlines the probable importance of AIF as a rate-limiting factor of the apoptotic process in vitro. Z-VAD.fmk has been designed for the inhibition of ICE-like proteases. However, AIF is not among the known members of the family of ICE/CPP32/Ced3-like proteases. Its molecular mass (~50 kD), subcellular localization, and proteolytic spectrum (notably the absence of PARP cleavage) are not compatible with those of known members of the ICE/CPP32/Ced3 family (11). In addition, preliminary NH2-terminal sequence data suggest that at least mouse hepatocyte AIF is encoded by a novel gene. Thus, it would be premature to consider AIF as an ICE-like protease, and the further characterization of AIF will require its cloning and genetic manipulation.

Is AIF the Principal Apoptogenic Factor? Our data suggesting a major role of AIF in the apoptotic process are compatible with previous reports that mitochondria are necessary to mediate apoptosis either in mammalian or in Xenopus laevis cells (15, 16) and that some known members of the ICE family such as ICE itself or CPP32 do not suffice to cause apoptosis in a cell-free system (14, 17, 30, 35). Moreover, our data are compatible with reported cell-free systems of apoptosis with regard to the particular ion requirements of AIF action, which functions in the presence of calcium chelators and at a neutral pH (13–17). In contrast, our results appear to be in conflict with the observation that mitochondria can be substituted for by ceramide to induce nuclear apoptosis in vitro (16). However, careful analysis reveals a major functional difference between AIF and ceramide. First, the apoptosis-inducing effect of ceramide on cells is antagonized by Bcl-2 (2), which is not the case for AIF (Fig. 7). Second, maximal doses of C2 ceramide require a minimum of 3 h to induce nuclear apoptosis in vitro (16), whereas high doses of AIF act within ~15 min (4). Thus, AIF rather than ceramide would be a rate-limiting apoptogenic factor. Nagata and co-workers have reported the existence of a cytosolic apoptogenic factor that is produced upon Fas-cross-linking (17, 35). The method of isolation to obtain this factor, repeated freezing and thawing, would destroy the activity of AIF. Interestingly, these authors have found that cytosolic extracts treated with recombinant CPP32 become apoptogenic (35). As a consequence, it cannot be excluded that, at least in Fas-induced apoptosis, other factors than AIF may be involved in the mediation of nuclear apoptosis. Further exploration of these poorly characterized in vitro systems will have to resolve this issue. As mentioned above, AIF fails to cleave nuclear PARP. Since the knock-out of the PARP gene has no major effects on apoptosis regulation, cleavage of this substrate is likely to constitute a consequence rather than a mechanism of apoptosis (36). However, since proteolysis of PARP is a common sign of nuclear apoptosis in cells (37) and in some cell-free systems of apoptosis (14, 25), additional (AIF-activated?) cytosolic proteases appear to be involved in the apoptotic degradation phase.

Mode of Action of Bcl-2. To unravel the relationship between AIF and Bcl-2, we have investigated three mutually non-exclusive possibilities. Bcl-2 might suppress (a) AIF synthesis; (b) AIF release; (c) or AIF action. Our data clearly indicate that Bcl-2-overexpressing mitochondria contain normal amounts of pre-formed AIF (Fig. 5, B and C), an observation that would be compatible with an eventual house-keeping function of this ubiquitous protein. Instead of preventing AIF formation (Fig. 5, B and C) or action (Figs. 6 and 7), Bcl-2 inhibits the PT-mediated release of AIF (Fig. 5, B and C). Our data suggest that Bcl-2 is primarily an inhibitor of PT (reference 4 and Fig. 5, A) in line with the facts that it is mainly situated in the inner-outer mitochondrial membrane contact sites (33, 34, 38) (where PT pores form[6]) and that its expression level correlates stoichiometrically with one of the putative PT pore constituents, the peripheral benzodiazepine receptor (39). Exploration of the mechanisms how Bcl-2 regulates PT-dependent AIF release will require further characterization of the PT pore complex.

In conclusion, Bcl-2 suppresses apoptotic PT and AIF release from mitochondria, yet does not interfere with the formation or action of AIF. This interpretation is in accord with previous genetic (40–43) and functional data (15, 43, 44), suggesting that, at least in some experimental systems, the mitochondrial but not the nuclear localization of Bcl-2 would determine its anti-apoptotic capacity. These results are also compatible with the absent or marginal apoptosis-
inhibitory effect of Bcl-2 on cell-free systems, when Bcl-2 protein is added to cytoplasmic extracts already containing soluble pro-apoptotic factors (15, 16).

**Hierarchy between Bcl-2- and Protease-controlled Check Points of the Apoptotic Cascade.** The present data may resolve a long-lasting controversy on the hierarchy between the putative control points of apoptosis regulated by Bcl-2/Ced-9 and ICE/Ced-3-like proteases, respectively (9-12, 31, 32). According to our data, Bcl-2 would prevent apoptosis by maintaining the subcellular compartmentalization of AIF, thereby suggesting a scenario that de facto abolishes the existence of such a hierarchy, at least at the level of the mitochondrial protease. However, it would be an oversimplification to assume that all proteases of the ICE/CPP32/Ced-3 family control the same point of the apoptotic cascade. Thus, ICE itself clearly acts upstream of the PT check point, in the sense that ICE activation triggered by Fas is an extremely rapid (<15-30 min) event (35) that precedes the PT-mediated \( \Delta \Psi_m \) collapse. Inhibition of ICE by Ac-YVAD.cmk prevents the \( \Delta \Psi_m \) disruption induced by Fas cross-linking (5). Moreover, recombinant ICE is a direct inducer of PT in isolated mitochondria (M. Castedo, S.A. Susin and G. Kroemer, manuscript in preparation). The protease inhibitors TLCK and Z-VAD.fmk can also prevent the glucocorticoid-triggered \( \Delta \Psi_m \) disruption in thymocytes (8), suggesting the implication of one or several Z-VAD.fmk-inhibitable proteases in the induction of PT. When combined with the facts reported in this paper, this observation can be interpreted in two different ways. As a first possibility, one type of Z-VAD.fmk-inhibitable protease(s) would act upstream and another one, AIF, downstream of the mitochondrion. As a second possibility, AIF (and AIF-activated proteases) might engage in a self-amplification loop in which an initial triggering of PT causes AIF release, which in turn favors PT. These scenarios are currently under active investigation.

**A Speculative Model of Apoptosis Regulation and Execution.** Current models of apoptosis subdivide the common pathway into an initial effector phase, during which the “decision to die” is still subject to regulatory mechanisms, and a later degradation phase, beyond the “point-of-no-return”, during which the progressive augmentation of entropy due to the activation of catabolic enzymes precludes further regulation (3). Collectively, our data can be embedded into the following working hypothesis (Fig. 8). Different pathways of apoptosis induction (some of which may involve ROS production, ICE activation, changes in the expression level of Bcl-2/Bax etc.) converge at the level of the mitochondrion to induce PT and an associated \( \Delta \Psi_m \) collapse. This event is controlled by Bcl-2 and probably by other Bcl-2 homologues located in the outer mitochondrial membrane. As a result of PT, which marks the point-of-no-return, the cell manifests multiple alterations: perturbation of the plasma membrane structure, increased production and action of superoxide anion, cytoplasmic changes, and nuclear apoptosis (2, 4, 8). At least some of these consequences of PT are dissociable among each other. Thus, the exposure of phosphatidylserine residues on the outer plasma membrane leaflet precedes hyperproduction of superoxide anions and does not require the presence of a nucleus (5); and nuclear apoptosis can be observed in ROS-free conditions (45). Hence, it appears that these manifestations of the degradation phase of apoptosis are not linked among each other via direct cause-effect relationships and are rather coordinated by a superior control event (8). Future investigations will have to determine to which extent the metabolic consequences of PT such as uncoupling of the respiratory chain or the PT-dependent AIF release function as coordinators of the apoptotic cascade.

In synthesis, the available data provide a plausible explanation for, as well as a number of testable hypotheses on the regulation of the apoptotic effector phase by proteases,
mitochondria, and proto-oncogenes of the Bcl-2 family. The progressive unmasking of the mechanism of action of Bcl-2, one of the major endogenous survival factors of lymphoid cells and one of the clinically most important onco-proteins, may have far-reaching consequences for the rational design of apoptosis-modulatory drugs.

We thank Drs. E. Nigg (Lausanne, Switzerland) for E6 antibody, Michel Galay, Claude Fudali, and Annie Guichard (Roussel Uclaf, Romainville, France) for reverse phase HPLC analysis, and Marisa Pellecato (Zaragoza, Spain) for advice in FPLC analysis.

Supported by Association pour la Recherche contre le Cancer, Fondation de France, Fondation pour la Recherche Médicale, Léo Foundation, Ligue Française contre le Cancer, NATO, and the French and Spanish Ministries of Science (to G. Kroemer). M. Geuskens is a senior research associate of the Belgian National Fund for Scientific Research. S.A. Susin receives a fellowship from the Spanish Ministry of Science.

Address correspondence to Dr. Guido Kroemer, 19 rue Guy Môquet, B.P. 8, F-94801 Villejuif, France.

Received for publication 16 May 1996 and in revised form 30 July 1996.

References

1. Zamzami, N., P. Marchetti, M. Castedo, C. Zanin, J.-L. Vaysière, P.X. Petit, and G. Kroemer. 1995. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. *J. Exp. Med.* 181:1661-1672.

2. Zamzami, N., P. Marchetti, M. Castedo, D. Decaudin, A. Macho, T. Hirsch, S.A. Susin, P.X. Petit, B. Mignotte, and G. Kroemer. 1995. Sequential unmasking of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. *J. Exp. Med.* 182:367-377.

3. Kroemer, G., P.X. Petit, N. Zamzami, J.-L. Vaysière, and B. Mignotte. 1995. The biochemistry of apoptosis. *FASEB J.* 9:1277-1287.

4. Zamzami, N., S.A. Susin, P. Marchetti, T. Hirsch, I. Gómez-Monterrey, M. Castedo, and G. Kroemer. 1996. Mitochondrial control of nuclear apoptosis. *J. Exp. Med.* 183:1533-1544.

5. Castedo, M., T. Hirsch, S.A. Susin, N. Zamzami, P. Marchetti, A. Macho, and G. Kroemer. 1996. Sequential acquisition of mitochondrial and plasma membrane alterations during early lymphocyte apoptosis. *J. Immunol.* 157:512-521.

6. Zoratti, M., and I. Szabó. 1995. The mitochondrial permeability transition. *Biochim. Biophys. Acta. Rev. Biomembranes.* 1241:139-176.

7. Nicoll, A., E. Basso, V. Petronilli, R.M. Wenger, and P. Bernardi. 1996. Interactions of cyclophilin with mitochondrial inner membrane and regulation of the permeability transition pore, a cyclosporin A-sensitive channel. *J. Biol. Chem.* 271:2185-2192.

8. Marchetti, P., M. Castedo, S.A. Susin, N. Zamzami, T. Hirsch, A. Haeffner, F. Hirsch, M. Geuskens, and G. Kroemer. 1996. Mitochondrial permeability transition is a central coordinating event of apoptosis. *J. Exp. Med.* 184:1185-1160.

9. Olvai, Z.N., and S.J. Korsmeyer. 1994. Checkpoints of dying: an overview of cell death. *Cell.* 79:189-192.

10. Martin, S.J., and D.R. Green. 1995. Protease activation during apoptotic death by a thousand cuts? *Cell.* 82:349-352.

11. Henkurt, P.A. 1996. ICE family proteases: mediators of all apoptotic cell death? *Immunity.* 4:195-201.

12. Chinnaiyan, A.M., K. Orth, K. Orouke, H.J. Duan, G.G. Poirier, and V.M. Dixit. 1996. Molecular ordering of the cell death pathway—Bcl-2 and Bcl-X(L) function upstream of the CED-3-like apoptotic proteases. *J. Biol. Chem.* 271:4573-4576.

13. Lazebnik, Y.A., S. Cole, C.A. Cooke, W.G. Nelson, and W.C. Earnshaw. 1993. Nuclear events of apoptosis in vitro in cell-free mitotic extracts: a model system for analysis of the active phase of apoptosis. *J. Cell. Biol.* 123:7-22.

14. Zamzami, Y.A., S.H. Kaufmann, S. Desnoyers, G.G. Poirier, and W.C. Earnshaw. 1994. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. *Nature (Lond.)* 371:346-347.

15. Newmeyer, D.D., D.M. Farschon, and J.C. Reed. 1994. Cell-free apoptosis in xeno-egg extracts: inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria. *Cell.* 79:353-364.

16. Martin, S.J., D.D. Newmeyer, S. Mathisa, D.M. Farschon, H.G. Wang, J.C. Reed, R.N. Kolesnick, and D.R. Green. 1995. Cell-free reconstitution of Fas-, UV radiation- and ceramide-induced apoptosis. *EMBO (Eur. Mol. Biol. Organ.) J.* 14:5191-5200.

17. Enari, M., A. Hase, and S. Nagata. 1995. Apoptosis by a cytosolic extract from Fas-activated cells. *EMBO (Eur. Mol. Biol. Organ.) J.* 14:5201-5208.

18. Green, D.R., A. Malhoubi, W. Nishioka, S. Oja, F. Echeverri, Y. Shi, J. Glynn, Y. Yang, J. Ashwell, and R. Bissonnette. 1994. Promotion and inhibition of activation-induced apoptosis in T-cell hybridomas by oncogenes and related signals. *Immunol. Rev.* 142:321-342.

19. Boutry, M., and M. Briqueil. 1982. Mitochondrial modifications associated with the cytoplasmic male sterility in fava beans. *Eur. J. Biochem.* 127:129-135.

20. Pedersen, P.L., J.W. Grennawalt, B. Reynafarje, J. Hullihen, G.L. Decker, J.W. Soper, and E. Bustamante. 1978. Preparation and characterization of mitochondria and submitochondrial particles of rat liver and liver-derived tissues. *Methods Cell Biol.* 20:411-481.

21. Desautels, M., and A.L. Goldberg. 1982. Demonstration of an ATP-dependent, vanadate-sensitive endoprotease in the matrix of rat liver mitochondria. *J. Biol. Chem.* 257:11673-11679.

22. Nummari, J., T.D. Fox, and P. Walter. 1993. A mitochondrial protease with two catalytic subunits of nonoverlapping speci-
26. Zhivotovsky, B., A. Gahm, M. Ankarcrona, P. Nicotera, and S. Orrenius. 1995. Multiple proteases are involved in thymocyte apoptosis. Exp. Cell Res. 221:404–412.

27. Pronk, G.J., K. Ramer, P. Amiri, and L.T. Williams. 1996. Requirement of an ICE-like protease for induction of apoptosis and ceramide generation by REAPER. Science (Wash. DC). 271:808–810.

28. Cain, K., S.H. Inayathussain, C. Couet, and G.M. Cohen. 1996. A cleavage-site-directed inhibitor of interleukin 1 beta-converting enzyme-like proteases inhibits apoptosis in primary cultures of rat hepatocytes. Biochem. J. 314:27–32.

29. Gershenson, G., K.L. Houmiel, and R.L. Low. 1995. Endonuclease G from mammalian nuclei is identical to the major endonuclease of mitochondria. Nucleic Acids Res. 23:88–97.

30. Nicholson, D.W., A. All, N.A. Thornberry, J.P. Vaillancourt, C.K. Ding, M. Gallant, Y. Gareau, P.R. Griffin, M. Labelle, Y.A. Lazebnik et al. 1995. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature (Lond.). 376:37–43.

31. Reed, J.C. 1995. Bcl-2 and the regulation of programmed cell death. J. Biol. Chem. 324:1–6.

32. Cory, S. 1995. Regulation of lymphocyte survival by the Bcl-2 gene family. Annu. Rev. Immunol. 13:513–543.

33. Krajewski, S., S. Tanaka, S. Takayama, M.J. Schibler, W. Fenton, and J.C. Reed. 1993. Investigation of the subcellular distribution of the bcl-2 oncprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res. 53:4701–4714.

34. Riparbelli, M.G., G. Callait, S.A. Tripodi, M. Cintorino, P. Tosi, and R. Dallai. 1995. Localization of the Bcl-2 protein to the outer mitochondrial membrane by electron microscopy. Exp. Cell Res. 221:363–369.

35. Enari, M., R.V. Talanian, W.W. Wong, and S. Nagata. 1996. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature (Lond.). 380:723–726.

36. Wang, Z.-Q., B. Auer, L. Stingl, H. Berghammer, D. Haidacher, M. Schweiger, and E.F. Wagner. 1995. Mice lacking ADPRT and poly(ADP-ribose)lation develop normally but are susceptible to skin disease. Genes Dev. 9:509–520.

37. Kaufman, S.H., S. Desnoyers, Y. Ottaviano, N.E. Davidson, and G.G. Poier. 1993. Specific proteolytic cleavage of poly(ADP)ribose polymerase: an early marker of chemother-apy induced apoptosis. Cancer Res. 53:3976–3980.

38. Hockenbery, D., G. Nuñez, C. Milliman, R.D. Schreiber, and S.J. Korsmeyer. 1990. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature (Lond.). 348:334–338.

39. Carayon, P., M. Portier, D. Dussossoy, A. Bord, G. Petitpretre, X. Canat, G. Le Fur, and P. Casellas. 1996. Involvement of peripheral benzodiazepine receptors in the protection of hematopoietic cells against oxygen radical species. Blood. 87:3170–3178.

40. Tanaka, S., K. Saito, and J.C. Reed. 1993. Structure-function analysis of the Bcl-2 oncprotein. Addition of a heterologous transmembrane domain to portions of the Bcl-2B protein restores function as a regulator of cell survival. J. Biol. Chem. 268:10920–10926.

41. Nguyen, M., P.E. Branton, P.A. Walton, Z.N. Oltvai, S.J. Korsmeyer, and G.C. Shore. 1994. Role of membrane anchor domain of Bcl-2 in suppression of apoptosis caused by E1B-defective adenovirus. J. Biol. Chem. 269:16521–16524.

42. Hanada, M., C. Aimesempe, T. Sato, and J.C. Reed. 1995. Structure-function analysis of Bcl-2 protein identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J. Biol. Chem. 270:11962–11969.

43. Greenhalf, W., C. Stephan, and B. Chaudhuri. 1996. Role of mitochondria and C-terminal membrane anchor of Bcl-2 in Bax induced growth arrest and mortality in Saccharomyces cerevisiae. FEBS Lett. 380:169–175.

44. Jacobson, M.D., J.F. Burne, and M.C. Raff. 1994. Programmed cell death and Bcl-2 protection in the absence of a nucleus. EMBO (Eur. Mol. Biol. Organ.) J. 13:1899–1910.

45. Jacobson, M.D., and M.C. Raff. 1995. Programmed cell death and Bcl-2 protection in very low oxygen. Nature (Lond.). 374:814–816.